November 20, 2024 (Toronto, Ontario) – LineaBio, a cell line company, today announced it has submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its flagship unmodified, off-the-shelf, Good Manufacturing Practices (GMP)-compliant induced pluripotent stem cell (iPSC) line, Linea 1. LineaBio was launched in 2023 by parent companies CCRM, […]
The site will add state-of-the-art CGT capacity and employ artificial intelligence and automation to achieve critical product supply efficiencies for North American and global biotherapy clients. Hamilton, ON., October 17, 2024 – Today OmniaBio Inc. will announce the opening of a new North American cell and gene therapy (CGT) manufacturing and artificial intelligence (AI) centre of
CDMO collaboration propels cell replacement therapy targeting Duchenne muscular dystrophy forward, with consequences for the role of AI in cell therapy. September 9, 2024 (BOSTON, MA and HAMILTON, Ontario) – Somite Therapeutics, a tech-bio company harnessing big data and AI to pioneer novel cell replacement therapies, and OmniaBio Inc., a technology-driven cell and gene therapy CDMO
CCRM and OmniaBio spin-off provides high-quality iPSC lines that expedite time to GMP by 12 months and reduce cell line development costs by up to 60%. July 30, 2024 (Toronto, Ontario) – LineaBio, a cell line company, today announced the launch of its catalogue of off-the-shelf induced pluripotent stem cell (iPSC) lines. The off-the-shelf iPSC
LineaBio launches off-the-shelf GMP iPSC lines to accelerate iPSC-based cell therapies Read More »
June 12, 2024 (Hamilton, Ontario) – OmniaBio Inc. is pleased to announce the appointment of Kenneth (Ken) L. Harris as its Chief Strategy Officer and Head of Artificial Intelligence (AI), strengthening its mandate of bringing maturity to cell and gene therapy (CGT) through focused CGT expertise in contract development and manufacturing. Harris, a seasoned executive
OmniaBio announces Kenneth L. Harris as Chief Strategy Officer and Head of AI Read More »
15 New projects underway to build world leading advanced manufacturing capabilities in Canada. TORONTO, ON, February 8, 2024 – NGen has announced over $32.3 million in Global Innovation Cluster funding for 15 new advanced manufacturing projects. With industry contributions of $54.4 million, the 15 projects are valued at a total of $86.7 million. The announcement
NGen Unveils $86.7 Million in New Advanced Manufacturing Projects at N3 Summit Read More »
CCRM Australia, with its Canadian partners OmniaBio Inc. and Toronto-based CCRM, has signed a Letter of Intent with The University of Queensland to establish the Advanced Cell Therapy Manufacturing Initiative (ACTMI)…
Advanced Cell Therapy Manufacturing Initiative To Be Established in Brisbane Read More »
The Canadian Advanced Therapies Training Institute (CATTI) Inc. has launched its first in-person training site at the University of Guelph…
Catamaran Bio Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, and OmniaBio Inc., a CDMO focused on…
OmniaBio Inc. has expanded its footprint by adding a new process and analytical development lab space at the McMaster University Medical Centre (MUMC)…
OmniaBio expands manufacturing footprint with second Hamilton location Read More »
